# A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer

Source: https://onco.cc/trials/nct07042802/  
OnCo record `nct07042802` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Paclitaxel / nab-paclitaxel, Bevacizumab in ovarian cancer, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.

## Summary

A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer is a phase 1/2 interventional study registered as NCT07042802 by Nanjing Leads Biolabs Co.,Ltd, with 180 participants planned, started 2025-12-02 and due to reach its primary completion in 2027-12-25. Interventions recorded: LBL-024 for Injection, Paclitaxel injection, Bevacizumab injection. Conditions listed: Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07042802
- Phase: 1/2
- Setting: An Open-label, Multi-center Phase Ib/II Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Paclitaxel Injection ± Bevacizumab in Patients With Platinum-resistant Ovarian Cancer
- Sponsor: Nanjing Leads Biolabs Co.,Ltd
- Enrolled: 180

## Sources

- ClinicalTrials.gov NCT07042802: https://clinicaltrials.gov/study/NCT07042802

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Nanjing Leads Biolabs](https://onco.cc/companies/nanjing-leads-biolabs/)

---
JSON: https://onco.cc/api/v1/entities/nct07042802.json